RELATED STUDY
Cannabinoid Attenuation of Intestinal Inflammation in Chronic SIV-Infected Rhesus Macaques Involves T Cell Modulation and Differential Expression of Micro-RNAs and Pro-inflammatory Genes
Key Findings: These translational findings strongly support a role for differential miRNA/gene induction and T cell activation in Δ9-THC-mediated suppression of intestinal inflammation in HIV/SIV and potentially other chronic inflammatory diseases of the intestine.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): United States
Year of Pub: 2019
Cannabinoids Studied: Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype I
Receptors Studied: CB2, PPAR - Gamma
Ligands Studied: Pro-inflammatory cytokines
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Injection
Cannabinoid Ratio: (THC) 0 
Dosing Regimen: THC at 0.18 mg/kg on a daily basis.
Titration: Dose was increased for each subject to 0.32 mg/kg, over a period of ~2 weeks when responding was no longer affected by 0.18 mg/kg
Treatment Duration: 180 days
Clinical Relevance: Δ9-THC shows the ability to prevent lymph node fibrosis, a serious irreversible consequence of HIV-induced chronic inflammation.
Link to study
